title: Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.
abstract: Prostate cancer presents high occurrence worldwide. Medicinal plants are a major source of novel and potentially therapeutic molecules; therefore, the aim of the present study was to investigate the possible anti-prostate cancer activity of afzelin, a flavonol glycoside that was previously isolated fromNymphaea odorata. The effect of afzelin on the proliferation of androgen-sensitive LNCaP and androgen-independent PC-3 cells was evaluated by performing a water soluble tetrazolium salt-1 assay. In addition, the effect of afzelin on the cell cycle of the LNCaP and PC-3 prostate cancer cell lines was evaluated. Western blot analysis was performed to evaluate the effect of afzelin on the kinases responsible for the regulation of actin organization. Afzelin was identified to inhibit the proliferation of LNCaP and PC3 cells, and block the cell cycle in the G0phase. The anticancer activity of afzelin in these cells was determined to be due to inhibition of LIM domain kinase 1 expression. Thus, thein vitroefficacy of afzelin against prostate cancer is promising; however, additional studies on different animal models are required to substantiate its anticancer potential.
authors.affiliation: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China ; Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Kai-Chang
authors.initials: KC
authors.lastname: Zhu
authors.affiliation: Department of Neonatology, Tongji Hospital, Tongji University, Shanghai 200065, P.R. China.
authors.forename: Jian-Mei
authors.initials: JM
authors.lastname: Sun
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Shen
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Ji-Zhong
authors.initials: JZ
authors.lastname: Jin
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Xu
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
authors.forename: Lin-Tao
authors.initials: LT
authors.lastname: Liu
authors.affiliation: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China.
authors.forename: Jia-Ju
authors.initials: JJ
authors.lastname: Lv
keywords: G0 phase; LIM domain kinase 1; LNCaP cells; PC-3 cells; afzelin; prostate cancer